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ABSTRACT 
 
IgG1 Fc is a remarkable molecule, capable of initiating pro-inflammatory or anti-
inflammatory responses by binding to Fc receptors. IgG1 Fc has a conserved glycosylation 
site at N297. The presence of the carbohydrate at N297 is vital for proper Fc function. 
Intramolecular glycan-polypeptide interactions are thought to impose conformational 
restrictions on Fc that maintain binding-favorable interactions. Perturbations of these 
intramolecular interactions may result in disrupted binding of Fc. In this work, we mutate 
residues at the glycan-polypeptide interface to disrupt the contacts between the glycan and 
polypeptide. Using MALDI-TOFMS and SPR we demonstrate that Fc mutants display more 
highly processed glycans and reduced affinity for FcγRIIIa. Furthermore, we mutate residues 
at the interface of the Cγ2 and Cγ3 domains that do not have highly processed glycans, but 
still have impaired binding to FcγRIIIa.  Finally, we conclude with a mIgG2a Fc protein 
construct that shows promise for testing Fc functionality in cellular systems.
 1 
CHAPTER 1 
INTRODUCTION: Fc STRUCTURE AND INTERACTIONS WITH RECEPTORS 
 
Introduction 
 Immunoglobulin G1 (IgG1) is a dual-function molecule in the immune system. 
IgG1 is a heterotetramer made up of two heavy chains and two light chains. Papain 
digestion of IgG1 results in two functionally distinct fragments: the fragment antigen 
binding (Fab) and the fragment crystallizable (Fc). A hinge region containing two 
disulfide bonds links the Fab and Fc fragments. Fab and Fc both retain their individual 
functions after proteolytic separation. The Fab recognizes and binds to specific epitopes 
via the variable domains of the heavy chain and light chain. Fc interacts with receptors to 
elicit effector functions such antibody-dependent cellular cytotoxicity (ADCC), 
compliment-dependent cytotoxicity (CDC), and intracellular antibody-mediated 
degradation. Fc is also able to initiate pro-inflammatory and anti-inflammatory responses 
(1).  
IgG1 Fc is released as a 52 kDa homodimer following papain digestion of the 
IgG1 molecule. Each monomer contains a Cγ2 domain and a Cγ3 domain (Fig 1). The 
Cγ3 domains of each monomer interact to form a dimer interface. The Cγ2 domain is the 
site of many receptor interactions and contains a conserved glycosylation site at N297.  
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Figure 1: IgG1 Fc structure. PDB ID: 1E4K 
 
This is a structural feature of note as the Fc N-glycan is required for interactions with 
receptors such as FcγRIIIa and FcγRIIa, but not TRIM21 and protein A.  
Many different crystal structures of IgG1 Fc have been solved (2-23). Co crystals 
of Fc and Fc ligands show Fc is capable of interacting with a diverse set of receptors (5-
7,12,13,19). The Fc N-glycan is at least partially resolved in many of the crystal 
structures(8-10,18,21). While the Fc N-glycan is necessary for proper function, the 
reasons for this are unclear from structures determined by x-ray crystallography. 
Although crystallographic data is limited by the structural constraints of molecules in the 
crystal lattic, the high resolution data provided by solving structures by x-ray diffraction 
is invaluable. When considered with solution information from NMR studies (15,24-27) 
and hydrogen-deuterium exchange mass spectrometry (HDX-MS) (28,29) a more 
complete picture of the dynamic nature of the Fc system emerges.  In this review, we aim 
to describe the current state of our understanding of Fc structure and dynamics, and  link 
this structural knowledge to our understanding of its biological function. 
Cg3 
Cg3 
Cg2 Cg2 
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Fc Structure 
Cγ2 Domain Orientations 
 The role of Fc is to interact with receptors to modulate the activity of the immune 
system. Fc gamma receptors (FcγRs) interact with Fc in the lower hinge region between 
Cγ2 domains (Figure 2). This means an FcγR forms an interface with both Fc Cγ2 
domains, thus, Cγ2 domain orientation is thought to be an important determinant of the 
Fc/FcγR interaction. 
 
Figure 2: A) Structural model of Fc-FcγRIIIa interaction, PDB ID: 3AY4. B) Structural model of Fc-
FcγRIIa interaction, PDB ID: 3RY6. Blue: Fc Chain A, Green: Fc Chain B, Pink: FcγRIIIa, Red: FcγRIIa, 
White: glycans 
 
Several conformations of the Fc have been observed, and differ mainly in the 
relative orientation of the Cg2 domains. Several parameters have been used to compare 
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differences between independent observations of Fc structures. It is thought that 
structures with Cg2 orientations that are closer or farther apart than that observed for the 
Fc:FcgRIIIa complex represent conformations that are incapable of binding FcgRs. These 
measurements provide a useful frame of reference for comparing Fc structures as 
determined by X-ray crystallography, but the biological relevance of these parameters is 
unclear. 
 One commonly reported measurement is the distance between P329 residues 
(17,18,21). P329 is located in the FG loop of the Cγ2 domain (Figure 3). Inter-P329 
distances are meant to describe the distance between Cγ2  
 
Figure 3: Fc Cγ2 loops serve as the FcγR binding site. The C`E loops contains N297, the FG loops 
contains P329. A) Fc monomer shown to emphasize the locations of the loops structures, PDB ID: 4Q7D. 
B) Co-structure of Fc and FcγRIIIa, the interaction between chain A and FcγRIIIa is emphasized here to 
show that all three Fc Cγ2 loops make contact with FcγRIIIa. PDB ID: 3E4K 
 
domains in Fc. The smallest reported P329 distance is 18.9Å in an aglycosylated Fc 
structure (21). This observation lead to the hypothesis that aglycosylated Fc assumes a 
Fc N-glycan 
A B 
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collapsed structure. However, an unpublished aglycosylated Fc structure, (PDB: 3DNK) 
has a P329 distance of 27.6 Å. The limitations of such measurements to reflect biological 
relevance of the observed structures suggests that a single distance measurement does not 
provide a comprehensive picture of Fc structure. Measurements between the amino acid 
residues P238, F241, R301, and C1 atom of Man4 have been used as additional points of 
reference to describe the space between Cγ2 domains (17,18). In addition to simple 
distance measurements, several groups have included the angle formed by the Cγ2 and 
Cγ3 domains (4,5). One group also included the dihedral angle of the Cγ2-Cγ3 domains 
(4). These angular measurements provide useful information because they help describe 
the asymmetry of the Fc dimer. 
 Many of the Fc structural models determined by x-ray crystallography form an 
asymmetric horseshoe shape. In Fc, asymmetry can occur two ways: by heterogeneous 
glycosylation of the Cγ2 domains, or by heterogeneity of the Cγ2 domain orientations. 
Likely, the asymmetry observed in crystal structures in due to the crystal packing of the 
Fc molecule. Based on molecular dynamic simulations, the Cγ2 domains of Fc are 
flexible and their orientations is space are not required to be symmetric (4). Asymmetry 
of Fc Cγ2 domains does make biological sense; FcgR binding breaks the two-fold 
symmetry of the Fc dimer.  
   
Cγ2-Cγ3 Interface 
 Another important structural feature of Fc is the Cγ2-Cγ3 domain interface. This 
interface plays an important role in restricting the overall domain motions of the Cγ2 
domains (4,17). Stability of this interface is due to salt bridges, hydrogen bonds, and a 
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hydrophobic “ball in socket” joint. Salt bridges formed by the glutamate-lysine pairs 
E380-K248 and E430-K338 seem to be particularly important in maintaining proper Cγ2 
orientations. A E380A / E430A Fc mutant showed increased flexibility of the Cγ2 
domains in 200 ns MD simulations (4). Interestingly, The E380A mutant by itself appears 
to only affect FcRn binding while E430A reduces affinity for only FcγRIIIa (30). L251 is 
likewise found at the Cγ2-Cγ3 interface as part of the “ball-in-socket” joint (Figure 4) 
(17).  
 
 
The N297 Glycan 
IgG1 Fc contains a conserved glycosylation site at N297. The Fc N-glycan is 
compositionally heterogeneous (31-33). The variability in Fc glycosylation is due to the 
activity of various glycosidases and glycosyltransferases in the golgi complex (34,35).  
Figure 4: L251 functions as part of a ball-in-socket joint that guides Cγ2 motions. L251 forms the 
“Ball” while E430, H435, and M428 form the “socket”. L251 is colored cyan to indicate it is part of the 
Cγ2 domain. M428, E430, and H435 are colored pink to indicate they are part of the Cγ3 domain. 
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Figure 5: Diagrams of N glycan compositions. A) Depiction of diasialyl Fc. Carbohydrate Numbering and 
glycosidic linkages of the Fc N-glycan are indicated.  The Core Fc glycan consists of residue 0-5, residues 
6 & 7 are elaborations. B) Common types of N-glycan species seen in the Fc literature. Red triangle: 
Fucose, Blue square: N-acetylglucosamine, Green circle: Mannose, Yellow circle: Galactose, Purple 
diamond: N-acetylneuraminic acid. 
 
The Fc N-glycan is primarily of a biantennary, complex-type with a high level of core 
fucosylation (>95%). A common motif found in all human Fc N-glycan structures is a 
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heptasaccharide composed of chitobiose linked to N297 followed by a branching 
trimannose structure with terminating N-acetylglucosamine (GlcNAc) residues on the 
non-reducing branch termini (Fig 5). The N-glycan can be further decorated with 
terminal galactoses then sialic acids, and occasionally the addition of a bisecting GlcNAc. 
In healthy human serum the Fc N-glycan is about 35% GlcNAc terminated, 50% Gal 
terminated, and 15% sialic acid terminated (36). This distribution is shifted in disease 
states, such as rheumatoid arthritis, where the GlcNAc terminated (G0F) dominates 
(37,38). Certain glycoforms are attributed to pro-inflammatory or anti-inflammatory 
activity (36).  The G0F glycoform is considered pro-inflammatory, while sialic acid 
terminated Fc is considered anti-inflammatory. Glycosylation at N297 is vital to proper 
function of IgG1 Fc. Aglycosylated or deglycosylated Fc does not bind the low affinity 
Fc gamma receptors (IIa, IIb, IIIa, IIIb) (39-41) but binding of the high affinity receptor, 
FcγRI, is preserved (10,42).  Furthermore, the composition of the N-glycan can modulate 
the affinity of Fc for Fc receptors (21,36,43-47). Terminal galactosylation improves the 
affinity of Fc for FcγRIIIa while the presence of a core fucose residue decreases the 
affinity of Fc for FcγRIIIa by 100-fold (48-51). Fc structures determined by X-ray 
crystallography revealed that solvent exposure of Y296 is the primary difference between 
afucosylated and fucosylated Fc (52). Co-crystal structures of afucosyl Fc with FcγRIIIa 
suggest that Y296 is preventing from forming an important contact with the N-162 
glycan of FcγRIIIa because is occluded by a fucose on the Fc N-glycan (12). 
Multiple reports have presented conflicting conclusions regarding the role of 
sialylation on FcγR affinity. Competition assays and an SPR analysis suggest that 
sialylation reduces the affinity of Fc for FcγRIIIa by 5 to 10-fold (31,53,54) , another 
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study found no change in binding affinity by sialylating wild-type Fc (10). Furthermore, 
the mechanism by which sialylation affects Fc affinity for FcγRIIIa is unclear. One 
explanation is that sialylation results in Fc conformational changes that inhibit binding to 
FcγRs (9,55). An alternative theory is that sialylation reveals structural features in Fc that 
promote interactions with DC-SIGN (56,57). 
N-glycans on many proteins are conformationally heterogeneous and must be 
removed to allow crystallization. The Fc N-glycan is unusual because density for nearly 
the entire N-glycan was observed in the first structure determined by x-ray 
crystallography (3). The electron density of all carbohydrate residues is not always 
resolved in structural models determined by x-ray crystallography. The core carbohydrate 
structure is typically resolved while terminal galactose and sialic acid residues are not 
always resolved. In some models, this is due to compositional heterogeneity of the N-
glycan. In other structures, this is thought to be due to conformational heterogeneity 
localized at the termini of the N-glycan. As we will discuss later, this conformational 
heterogeneity may be due to the intrinsic mobility of the glycan chains (24).  
 
 
Fc-Fc Receptor Interactions 
 Interactions between the Fc region of immunoglobulins and Fc receptors links the 
humoral and cellular immune responses. The Fc receptor family is comprised of one high 
affinity receptor (high nanomolar affinity), FcγRI, and several low affinity receptors 
(high micromolar affinity), FcγRIIa, FcγRIIb, and FcγRIIIa (58-61). FcγRs are, in general, 
activating receptors except for the inhibitory FcγRIIb. These interactions modulate the 
immune response. Fc can trigger further effector functions via interactions with TRIM21 
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and C1q. Fc is also able to interact with the neonatal Fc receptor, FcRn, which is 
responsible for recycling antibodies and preventing degradation, and transcytosis of IgG 
across the placenta (62,63).  Being able to target specific receptors is desirable for the 
development of antibody based biotherapeutics. This has created much interest in 
understanding the basis of Fc-Fc receptor interactions. In this section, we will discuss the 
current evidence and models for these interactions.  
FcγRIIIa 
FcγRIIIa interacts with the lower hinge region, the BC-loop, the C`E loop 
(containing N297), and the FG loop of Fc (12,64-67).  The intermolecular polypeptide 
contact surface between the receptor and Fc is quite extensive. Depending on the 
structural model referenced, the contact surface area between Fc and FcγRIIIa is between 
1200 Å2 to 1700 Å2  (12,66). This contact surface is not symmetrically distributed 
between the two Fc monomers. The majority of the interaction is between the A chain of 
Fc and FcγRIIIa (12,66). This asymmetric binding mode is potentially advantageous as it 
opens the door for an alternative protein engineering route in asymmetric Fcs that allow 
for increased strength and specificity of Fc-FcR interactions (68-71).  
We previously introduced the importance of Fc glycosylation in Fc-FcγR 
interactions (see the section The N297 Glycan). FcγRIIIa glycosylation is also an 
important factor. There are five glycosylation sites on FcγRIIIa. Of these sites, only N162 
and N45 appear to have influence on Fc-FcγRIIIa interactions. As mentioned previously, 
fucosylation of Fc blocks the FcγRIIIa N162 glycan from interacting with Y296 of Fc 
(12,52). This interaction is specific for the N162-linked glycan on FcγRIIIa as removal of 
the glycan promotes interactions with fucosylated Fc (72). The N45 glycan is thought to 
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have an inhibitory effect on binding; removal of the N45 glycan promotes Fc-FcγRIIIa 
interaction (72,73). One theory for the inhibitory effect of the N45 glycan is that steric 
clash between the N45 glycan the chain B of Fc block Fc-FcγRIIIa interactions. However, 
solution evidence is needed to support this theory. 
Several mutant Fcs have been generated to influence the interaction between Fc 
and FcγRIIIa. Shields and colleagues performed a detailed mapping study using Fc 
mutants to describe many Fc-Fc receptor interactions (30). Several of the residues 
identified in this study make contact with FcγRIIIa in co-structures determined by x-ray 
crystallography (5,6,12,74). S239 and L235 on both Fc chains form contacts with 
FcγRIIIa. While Fc residues 327-330 (The FG loop, see Figure 3) on the B chain make 
contact with FcγRIIIa.  
The Fc triple mutant, S239D/A330L/I332E, has been reported to increase the 
affinity of Fc for FcγRIIIa 10-100 fold (6). The authors suggest that this triple mutant 
introduces new hydrophobic contacts via the A330L substitution and new hydrogen 
bonds/electrostatic interactions via S239D and I332E. Another Fc triple mutant, 
L234F/L235E/P331S, has impaired affinity for FcγRIIIa and other FcγRs (5). Most likely 
this reduction in affinity is due to the L235E mutation, which replaces a hydrophobic 
contact with a highly charged group. 
 
FcγRII 
 There are two FcγRII isotypes: FcγRIIa, which is a low-affinity, activating Fc 
receptor, and FcγRIIb, which is inhibitory (58,59,75). The major difference between the 
two the presence of a cytosolic immune receptor tyrosine activating motif (ITAM) in 
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FcγRIIa and an immune receptor tyrosine inhibitory motif (ITIM) in FcγRIIb. There is 
89% sequence identity at the amino acid level between the extracellular domains of 
FcγRIIa and FcγRIIb. The crystal structure of the soluble extracellular domains of 
FcγRIIa (76) and FcγRIIb (77) show similarities between FcγRIIa and FcγRIIb. 
Alignment of FcγRIIA and FcγRIIB structural models reveals an RMSD of only 1.1 Å 
(Figure 6).  
Isolated FcγRIIa and IIb both crystallize as dimers (76,77). This observation lead 
some researchers to suggest that two FcγRII moleculaes could interaction with a single 
Fc. However, costructures of Fc with FcγRIIa showed a single FcγRIIa receptor bound at 
the lower hinge region of IgG Fc, much like the previously mentioned FcγRIIIa (13). 
Sedimentation equilibrium and NMR experiments confirmed the binding stoichiometry 
was 1:1 and the lower hinge was identified as the binding site (78-80) and this hypothesis 
is supported by ITC data (81).  
 
FcgRI 
 Unlike FcγRIIa and FcγRIIIa, there is no co-structure of Fc and FcγRIa, thus a 
high-resolution model for the interaction is unavailable. The structure of the extracellular 
domains of FcγRIa has recently been solved (82). There are several differences between 
FcγRI and the rest of the FcγR family, the most prominent of which is the presence of a 
third extracellular domains (83). Additional differences between FcγRI and other FcγRs 
include FcγRI being a high affinity receptor, having low nanomolar affinity for Fc, and 
the ability of FcγRI to bind Fc independent of Fc glycosylation (10,42). Furthermore, 
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FcγRI can bind monomeric Fc on cell surfaces, which may not have physiological 
significance, but does further distinguish FcγRI from other FcγRs (84).  
The exact reason behind this increased affinity has been debated. Early research 
suggested the third domain was responsible for improved affinity in mice (85). In this 
study, removal of the third domain in FcγRI removed the high affinity recognition of Fc. 
Introducing the third domain to FcγRII in mice made them high affinity receptors. Later, 
the second domain was identified as also playing a role in promoting high-affinity 
interactions between FcγRI  and Fc(86). Recent studies support the role of the second  
Figure 6: Alignment of FcγRIIa and FcγRIIb structures. Structures were aligned in PyMol. The RMSD 
value for the two FcγRII structures is 1.1 Å. Red: FcγRIIa, PDB ID: 1FCG. Green: FcγRIIb, PDB ID: 
2FCB 
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domain in increasing binding, and contest the importance of the third domain (82,87). 
Swapping residues 171-176 of FcγRI, located in the second domain, for the same 
residues in FcγRIIIa increases the affinity of FcγRIIIa for Fc 15-fold (82). The third 
domain does not appear as important as it is positioned away from the interaction site. 
The differences between the early studies and these more recent studies may be that 
earlier studies focused on mouse systems, while more recent research focuses on human 
systems.  
 
 
Figure 7: Structure of FcγRI solved by crystallography. PDC ID: 3RJD  
 
FcRn 
The neonatal Fc receptor, FcRn, is unique among Fc receptors. Named initially after its 
role in transporting IgG across the placenta, FcRn does not serve a signaling function. 
C1 
C2 
C3 
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Rather it is responsible for transcytosis of IgG and recycling endocytosed IgG back to the 
serum (58,63,66). FcRn interacts with the Cγ2-Cγ3 interface of Fc, and not the lower 
hinge region like FcγRs (88) (Figure 8a). The interaction between Fc and FcRn is pH 
dependent, exhibiting tight binding to Fc at pH 6 and weak binding at pH 7.4 This pH 
dependence allows for tight binding between FcRn and IgG in lysosomes, then release of 
IgG in neutral environments. In mice, the pH dependence is thought to be due to salt 
bridges created by Fc H435/FcRn E132, Fc H436/FcRn D137, and Fc H310/FcRn E117 
(Figure 8b). In humans the salt bridge pairs between H435-E132 and H310-E117 still 
exist, but residue 436 is a tyrosine. 
Engineering of Fcs to maximize interactions with FcRn is desirable for increasing 
the serum half-life of Fc based therapeutics. To do this, the binding at pH 6.0 should be 
selectively improved (89). An example of an Fc that has been modified for improved 
FcRn interaction is the Fc YTE mutant (M252Y/S254T/T256E)(89,90). This mutant 
Figure 8: ACostructure of Fc bound to FcRn. Orange: FcRn, Peach: beta macroglobulin, Blue: Fc. B) 
Key salt bridges formed between Fc and FcRn are responsible for the pH dependence of the interaction. 
 
A 
B 
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binds FcRn with a 10-fold greater affinity, but at the cost of a 2-fold decrease in affinity 
for FcγRIIIa (90). This mutation does not cause structural perturbations in the Fc 
structure, having an RMSD of only 0.86 Å when compared to Wt Fc (7). However, S254 
mutations are reported to impair FcγRIIIa interactions (30).  
Many other mutants have been shown to promote interactions between Fc and 
FcRn (30). T307A/E380A/N434A demonstrates a 16-fold increase in binding to isolated 
hFcRn and a 3.3-fold increase in binding to cells expressing FcRn (91). T250Q/M428L 
has a 30-fold increase in serum half-life that is pH dependent (92). The mutant 
H433K/N434F also has a 16-fold increase in affinity for FcRN at pH 6.0, but ironically 
has a 4-fold reduction of half-life in mice (93). Mutants that increases FcRn affinity 
without affecting other FcR interactions could be useful for increasing the effectiveness 
of biotherapeutics (63,94). Those that do have impaired affinity for other FcRs are useful 
as Abdegs; antibodies that promote the degradation of pathogenic Igs by preventing their 
recycling by FcRn (95).  
  
DC-SIGN 
DC-SIGN is an inhibitory receptor on dendritic cells and macrophages that 
traditionally interacts with high mannose type glycans to recognize pathogens. While not 
a traditional Fc receptor, it was proposed that interactions between sialyl-Fc (sFc) and 
DC-SIGN explain the anti-inflammatory effects of sFc (54,96). Removal of SIGN-R1, a 
DC-SIGN homolog, in mouse models of arthritis abrogates the effect restorative effects 
of IVIG, but adding human DC-SIGN restores its functionality (97,98). The structural 
explanation for this interaction suggests a conformational change in sFc, revealing sialic 
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acids, as the basis for the interaction between sFc and DC-SIGN (56). This study also 
suggests that the position of the sialic acid on the 3 arm of the Fc N-glycan could place it 
near the potential DC-SIGN binding site at the Cγ2-Cγ3 interface. 
A small number of published studies refute the formation of a complex between 
sFc and DC-SIGN. One study using carbohydrate arrays shows that sialylation of certain 
epitopes, like Lewis X, prevents interaction with DC-SIGN (99). Additionally, no 
conformational change is observed in Fc upon sialylation (9,15).  Furthermore, sFc does 
not compete with DC-SIGN ligands and binds no better than deglycosylated Fc (55). One 
theory is Fab cross-reactivity, and not Fc sialylation, allows IVIG to interact with DC-
SIGN (55). 
 
TRIM21 
 The Fc Receptor TRIM21 is a member of the tripartite motif family of pathogen 
defense proteins. TRIM21 plays an important role in viral defense by binding to 
intracellular IgG-virus complexes. TRIM21 marks these complexes for degradation by 
the proteasome, destroying the virus and bound antibody (100). It should be noted that 
enveloped viruses can shed IgG before infecting a cell, and thus do not initiate a 
TRIM21-mediated response. Additionally, the anti-viral capabilities of TRIM21 can be 
overcome by superinfection (101). However, knockout studies in mice have shown that 
TRIM21 is necessary for antibody-dependent intracellular neutralization. 
 TRIM21 has low nanomolar affinity for IgG and is able to compete with protein 
A for Fc binding (101-104). TRIM21 binds to Fc at the Cγ2-Cγ3 interface (Figure 9) 
(100). This binding location allows two TRIM21 proteins to interact with one Fc 
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(103,104). Similar to FcRn, the TRIM21-Fc interaction is mediated by salt bridges. D355 
on TRIM21 forms salt bridges with H433 on Fc while D352 on TRIM21 forms a salt 
bridge with H435 on Fc. Even though the salt bridges formed by TRIM21 and Fc are 
similar to the FcRn-Fc complex, the TRIM21-Fc interaction does not appear to be 
dependent on pH (104). Two W residues, W381 and W383 were also identified as 
important residues by alanine scanning, perhaps forming important hydrophobic 
interactions 
 
 
 
Figure 9: Costructure of Fc with the PRYSPRY domain of TRIM21. Blue:FC, Seafoam: TRIM 21. PDB 
ID:  2IWG 
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General Theories of The Fc N-glycan Requirement 
 Of the receptors discussed above, the low-affinity FcgRs and DC-SIGN require 
Fc N-glycosylation, while Trim21 and FcRn do not. Here we will discuss the potential 
structural consequences of Fc N-glycosylation to binding the low-affinity FcgRs. Two 
primary theories behind why the N-glycan is required for the Fc-FcγR interactions have 
been proposed. These theories are not mutually exclusive. The first is the orientation of 
the Cγ2 domains influences the affinity of Fc-FcγR interactions (11). This theory 
proposes that Fc samples a range of conformations, some predisposed to bind with the 
receptor binding site easily accessible and others with conformations, either too wide or 
narrow, disfavoring Fc-FcgR interactions. In this model glycan composition is proposed 
to influence Cγ2 orientations, with pro-inflammatory glycoforms assuming a small set of 
properly organized conformations and anti-inflammatory glycoforms incapable of 
binding. Aglycosylated or deglycosylated Fc is proposed to assume a “collapsed” 
conformation, where binding of the receptors is unfavorable. 
 The second proposed model is that the local dynamics of the CE loop influences 
the ability of receptors to interact with Fc molecules  (23,52,105). In this model, the role 
of the glycan is to restrict the motion of the CE loop, holding it in a proper conformation 
for FcR binding. It is possible that both the Cγ2 domain orientation and CE loop disorder 
contribute to FcγR affinity. The role of the N-glycan, then, may be determining what 
conformational ensemble is sampled by the CE loop and/or the Cγ2 domains, and how 
frequently binding conformations are assumed. Here we will discuss the evidence related 
to the structure/activity relationship of the Fc N-glycan. This area still holds multiple 
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unanswered questions and lacks definitive evidence that favors one of these two 
hypotheses. 
 
Glycan Motions 
The Fc N-glycan is Dynamic 
 Based on crystal structures, the Fc N-glycan was initially thought to remain bound 
between the two Cγ2 domains of the homodimer (2,3). However, the Fc N-glycan is 
sensitive to enzymatic modifications in the golgi and in vitro, suggesting the Fc N-glycan 
must populate exposed conformations at some frequency. 
 A clear relationship between glycan composition and glycan function has long 
been of interest. Early NMR relaxation experiments comparing normal and rheumatoid 
Fc samples showed that 18 protons in normal Fc samples experienced slow relaxation 
rates and 41 protons in the rheumatoid sample exhibited slow nuclear relaxation (106). 
The major difference between normal and rheumatoid samples was that rheumatoid 
samples had fewer galactose-terminated glycans. This lead to the conclusion that 
galactosylation restricts glycan motions by promoting interactions with the polypeptide. 
Previously mentioned galactose labeling studies have further demonstrated that the G2F 
glycoform has a dynamic nature, where the 6-arm interconverts between polypeptide-
bound and solvent exposed states (24,26). However, we understand little about the other 
biologically relevant glycoforms. 
 When the dynamics of the Fc N-glycan were first examined by ESR they were 
thought to be on the same order as the Cγ2 domains (107-109). As technology advanced, 
NMR became a powerful tool for study the dynamics of systems. Wormald and 
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colleagues measured relaxation rates of the IgG1 Fc N-glycan and noted that they were 
lower than those of the bulk protein (25). Their conclusion was that the glycan was, in 
fact, quite mobile. Shortly after this study, Yamaguchi and colleagues used a  13C-
galactose labeling strategy was used to further refine our understanding of this dynamic 
system (26). According to their solution NMR results the 6-arm galactose of the glycan 
experienced motion that was similar to the polypeptide backbone indicating a strong 
interaction between the two, but the 3-arm galactose residue was significantly more 
mobile indicating motion that was not restricted by the polypeptide.  
The findings by Yamaguchi et al (1998) were challenged by Barb and Prestegard 
(2011) who used Fc remodeled with 13C2 galactose to thoroughly characterize the motion 
of the Fc-N-glycan using solution NMR spectroscopy. These studies revealed that 
surprisingly both branches of the Fc N-glycan were mobile (24). The broad lines 
observed by Yamaguchi et al could be explained by slow µs motions of resonances on the 
6-arm, however, it was quite clear that the branch termini experienced significant motion 
at physiological termperature. These NMR data revealed that the 3-arm appeared to 
experience one state, while the 6-arm experiences two states: one a polypeptide-bound 
state and the other a solvent exposed state. 
Further exploration of Fc glycan motions began with a look at the function of 
ST6Gal-I. ST6Gal-I is a sialyl transferase that adds sialic acids to galactose terminated N-
glycans (110,111). ST6Gal-I has a branch preference for the 3-arm of the Fc N-glycan, 
even when the glycan is released from the polypeptide surface (112). The conservation of 
relative branch modification by St6GalI was similar for Fc-conjugated and free N-
glycans, indicating the innate branch specificity of St6GalI was not influenced by the Fc 
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polypeptide. This result suggested the Fc N-glycan samplings conformations that have 
both branch termini either simultaneously exposed or restricted from access by the 
enzyme.  
Sialylation of Fc is known to increase the anti-inflammatory activity of IgG1 Fc 
(36,54,97,113-115). However, it does not appear to have a significant impact on glycan 
motions (15). In fact, sialylation appears to have little influence on the interaction 
between the Fc N-glycan and the polypeptide (9,18). Sialylation is reported to have an 
opening effect on Fc Cγ2 domains based on a structural model solved by x-ray diffraction, 
but this is currently unsupported by solution data (18).  
 
The Relationship Between glycan dynamics and receptor interactions 
The exact mechanism behind the relationship between glycan composition and the 
ability of Fc to interact with FcγRs remains undefined. One prevalent theory suggests 
glycan composition affects the relative orientation of the Fc Cγ2 domains (22,56,57). 
This is supported by crystallographic evidence. Other theories propose more subtle 
conformational changes in the interacting loops on Fc are responsible (23,52,105). The 
truth may be some combination of these two theories. While our understanding of this 
incredibly intricate system has come a long way, we still need information about the 
solution behavior of Fc to complete the picture. 
Interactions between the Fc polypeptide and N-glycan determine how dynamic 
the glycan can be (116). Residues F241, F243, D265, V264, K246, and R301 have been 
identified as key residues in the glycan-polypeptide interaction (10,105,116). Mutation of 
these residues to disrupt their interaction with the glycan increases the amount of post-
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translational processing of the glycan. Disrupting these interactions influences the 
conformations sampled by Fc, thereby altering its ability to interact with receptors 
(10,18). However, Fc already samples a broad range of conformations (Figure 4) (4,18).  
F241 mutants have received the most attention. The F241A mutation abrogates 
the π-CH interaction between F241 and GlcNAc2 (105).  Structural models of the F241A 
mutant have been determined by X-ray crystallography (10,18). It was noted that electron 
density of the 3-arm is reduced in the F241A mutant (10). However, crystallographic 
evidence only hints at motions at best. F241S is a mutant that is similar to F241A in 
terms of Fc glycoform distribution. Both F241A and F241S have a heightened level of 
sialic acid terminated Fc glycans. NMR measurements of 13C2 Gal labeled Fc F241S 
spin relaxation rates are smaller for the 6-arm versus wild type (116). This means that for 
the F241S mutation the Fc N-glycan is more mobile. 
Not only do mutations at F241 result in a more mobile glycan, they also affect Fc-
Fc receptor interactions. An early study of F241A showed that, compared to mutations 
like F243A, F241A had negative impact on effector functions (105). F241A had a 2.3-
fold decrease in C1q binding, and a 1.6-fold decrease in FcgRI binding. These 
observations were attributed to potential shifts in the conformation of the lower hinge 
region of the Cγ2 domain.  
Our lab recently determined that increasing glycan mobility in correlated with 
reduced affinity for FcγRIIIa (116). Residues F241, F243, and K246 were mutated to 
perturb the Fc glycan-polypeptide interaction. F241S/F243S double mutants had 
considerable increases in glycan mobility and decreases in FcγRIIIa affinity. K246F 
appeared to stabilize the Fc N-glycan, reducing mobility, while promoting FcγRIIIa 
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interaction. Mobility of the 6-arm is more strongly correlated with FcγRIIIa affinity. 
Considering the 3-arm is already more mobile, this makes sense that changes in the 
relatively immobile 6-arm would have a more dramatic effect. Some of the experiments 
that contributed to this conclusion are discussed in the following chapters. 
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CHAPTER 2 
MUTATIONAL STUDIES OF IgG1 FC-FcγRIIIA INTERACTIONS 
 
Introduction 
Rheumatoid arthritis (RA) afflicts 1.5 million people in the United States (117). 
As the disease progresses, it can have a crippling effect. Production of autoantibodies is 
one of the hallmark signs that diseases, such as RA, have developed. However, the 
development of autoantibodies only accounts for changes in the Fab region of antibodies, 
the region that recognizes antigens. The Fc region also experiences changes correlated 
with these diseases (37). While Fc does not have variable regions like Fab, the 
glycosylation profile of Fc is susceptible to change. This change in glycosylation profile 
occurs for the entire IgG repertoire, not just autoantibodies (118,119). In the case of 
many autoimmune diseases, marked changes in the glycosylation profile of Fc is 
correlated with the onset of the disease. 
IgG1 Fc contains a conserved N-glycosylation site at asparagine 297. N-
glycosylation is a co-translational modification that occurs in the rough ER. After the 
protein is folded, the nascent glycan is further processed in the golgi by a variety of 
glycosyl transferases (35). In the case of the Fc, sialylation by ST6Gal1 can occur after 
excretion into the blood stream (110). In vivo, factors such as transcriptional activation of 
the genes, the restriction of the N-glycan by contacts with the Fc polypeptide, and the rate 
of processing through the golgi affect the final outcome of the glycan profile 
(8,10,105,120-122). In vitro, perturbing the contacts between the Fc N-glycan and 
polypeptide increases the extent of enzymatic glycan processing (10,18,42,116). 
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The Fc N-glycan was initially thought to be relatively immobile, as discussed in 
the previous chapter, because of the ability of crystallographers to resolve the electron 
density of the glycans back in the 1970s (2,3). As work in this field developed, it turns 
out the glycan is quite mobile, forming transient contacts with polypeptide surface of Fc 
(24). This mobility is related to how accessible the glycan is to enzymes that modify the 
N-glycan (112). Additionally, the mobility of the N-glycan is correlated with the affinity 
of Fc for FcγRIIIa (116).  
The focus of this chapter is on work that looked into the role of glycan-
polypeptide interactions in Fc in order to understand the role of the N-glycan. The glycan 
is ultimately remodeled to make the glycoform of protein mutants homogeneous. 
Additionally, some work is done at the interface between the two constant domains of Fc 
to try and see if perturbation of Fc function could be independent of glycoform. Much of 
this work has already been published in Subedi, Hanson, and Barb (116). 
 
Methods 
Frustration Analysis and Alanine Scanning 
 Several Fc Cγ2-Cγ3 interface mutants were identified using a combination of 
frustration analysis and computation mutation scanning. Frustration analysis was done 
using the protein frustratometer webserver (123). The pdb file, 1FC1, was uploaded 
directly to the webserver. The results were visualized using PyMol. Mutation scans were 
performed using PyRosetta (124).1FC1 was prepared for alanine scanning first by 
removing all non-protein residues from the 1FC1 structure. The Cγ2 and Cγ3 domains in 
an FC monomer were then redefined as two separate, but interacting, chains: chain A and 
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chain B. Chain A, the Cγ2 domain, was defined as residues 238-341 in the model. Chain 
B, the Cγ3 domain, was identified as residues 342-444. The interaction interface was 
defined as all residues on one chain within 5A residues on the other. All residues 
identified as interacting residues were then individually mutated to a desired residue. 
Then ΔΔG values for the interaction between chain A and B were calculated by 
PyRosetta. 
Designing/selecting mutants 
The pGen2:hIgG1 Fc construct was made by cloning human IgG1 Fc (residues 
216-447) into the pGen2 vector at the NotI/HindIII restriction sites (From Dr. Adam Barb, 
Iowa State University). Residues F241, F243, K246, and D265 have been previously 
identified as residues that participate in intramolecular interactions between the Fc N-
glycan and polypeptide (105). T299 is part of the N-glycosylation consensus sequence, 
N-X-S/T, and was therefor mutated to create aglycosylated Fc. Fc Cγ2-Cγ3 interface 
residues were identified via frustration analysis and mutation scanning as stated above. 
All mutations were made by site directed mutagenesis. Initial primers were 
designed using the Quickchange Primer Design tool on the Agilent Technologies website 
(https://www.genomics.agilent.com/primerDesignProgram.jsp). Melting temperature and 
the formation of hair-pin loops were checked using the OligoAnalyzer 3.1 tool on the 
IDT website (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/). Successful 
mutation of the plasmid was confirmed by sequencing the constructs at the Iowa State 
University DNA Facility. 
Protein Expression and Purification 
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 Fc and GFP-FcγRIIIa proteins were expressed by transiently transfecting 
HEK293F cells (Life Technologies) or HEK293S (lec1-/-) cells with pGen2:IgG1 Fc 
(125). HEK293F were grown in FreeStyle293 medium (Life Technologies) at 37o C, 125 
RPM, 80% humidity, and 8% CO2. HEK293S cells were supplemented with 10% ExCell 
medium during growth. Transfections for both cell lines were done at cell densities of 2.5 
x 106 live cells/mL using 2.5 µg/mL of DNA with 7.5 µg/mL PEI. 24 Hours after 
transfection HEK293F cells were diluted 1:1 using FreeStyle293 medium supplemented 
with 4.4 mM valproic acid. HEK293S cells were diluted using FreeStyle293 medium 
supplemented with 4.4 mM valproic acid and 20% ExCell medium. After 5-6 days of 
growth, proteins were harvested from cells by centrifuging the cells at 1000xg for 5 mins 
and collecting the supernatant.  
IgG1 Fc was purified by applying the supernatant from the expression culture to a 
5 mL Protein A-sepharose column. The column was washed using three column volumes 
of 25 mM MOPS, 100 mM NaCl, pH 7.2. Bound Fc was eluted from the column using 
100 mM Glycine, pH 3.0; the eluent was collect in an equal volume of 1.0 M Tris, pH 8.0, 
to neutralize the elution buffer. IgG1 Fc was buffer exchanged into 25 mM MOPS, 100 
mM NaCl, pH 7.2 using a 15 mL Amicon Ultra centrifugal filter (Millipore) with a 10 
kDa filter.  
The supernatant from a GFP-FcγRIIIa expression was harvested as stated 
previously, and applied to a 5mL Ni-NTA column. The column was washed with three 
column volumes of 25 mM MOPS (pH 7.2), 100 mM NaCl, and 25 mM Imidazole. 
Bound proteins were eluted from the column with five column volumes of 25 mM MOPS 
(pH 7.2), 150 mM NaCl, and 50-250 mM imidazole, starting at 50 mM for the first 
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elution and ending at 250 mM. Imidazole was removed from the buffer using Amicon 
Ultra Centrifugal filters as stated above. 
Glycan Analysis (MALDI-TOF-MS) 
 Glycoforms of IgG1 Fc constructs were analyzed by MALDI-TOF-MS (126). 
Glycan samples were prepared by boiling the protein sample for 5 minutes, cooling it on 
ice, then digesting it with trypsin for 24 hours at 37o C. Glycans were released from 
trypsinized samples using PNGaseF. The released glycans were separated from protein 
fragments using a C18 cartridge. The purified glycan samples were permethylated by 
reacting them with iodomethane, and the samples dried down under N2 gas. The dried 
glycan samples were resuspended in 20 µL of anhydrous methanol. 2 µL of resuspended 
samples was combined with an equal volume of 1 mg/mL dihydroxy benzoic acid in 50% 
methanol/water and plated on a MALDI plate. Mass analyses was performed by MALDI-
TOFMS using a Voyager-DE Pro instrument at the ISU Protein Facility. Glycan 
remodeling to the G2F glycoform was done as reported in reference (116). 
Binding Analysis 
ITC 
 Isothermal titration calorimetry was used to measure the binding of wild type 
IgG1 Fc to GFP-sFcγRIIIa. IgG1 Fc was concentrated to 166 µM and titrated into 20 µM 
GFP-sFcγRIIIa using a MicroCal iTC 200 system (GE Healthcare). 2 uL of Fc were 
titrated 18 times at 25C with 3 minutes between injections. Two control experiments, one 
with buffer for the titrant and the other using buffer for the analyte, were also performed. 
The data from the control experiments were subtracted from the Fc to GFP-FcγRIIIa 
titration. The resulting binding isotherm was fit using a 1:1 interaction model. 
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Pull-down 
First, protein A sepharose beads were washed extensively with a buffer containing 
25 mM MOPS, 100 mM NaCl, and 0.25 mg/mL BSA, pH 7.4. Washed beads were 
suspended in a volume of buffer such that the resulting slurry was 50% (v/v) beads. GFP-
FcγRIIIa (0, 0.1, 0.3, 1, 3, and 6 µM) was mixed with IgG1 Fc (0, 0.1, 0.3, 1, 3, and 6 
µM) and incubated at room temperature for 5 min. After incubation, protein A beads 
were added. The mixture was incubated at room temperature for three minutes with 
periodic gentle vortexing to ensure a homogenous bead distribution. Supernatant was 
then separated from the beads following centrifugation at 500 g. Supernatant fluorescence 
was measured using a Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies) (ex-484 nm em-510 nm). The fraction of fluorescence bound to the beads 
at each point was determined by comparing to the total amount of fluorescence in a 
reaction without Fc added. Dissociate constants (KD) were determined by fitting Eq 1 to 
fractional occupancy data. 
Eq 1: 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙  𝑂𝑐𝑐𝑢𝑝𝑎𝑛𝑐𝑦 =   𝐹𝑐𝛾𝑅𝐼𝐼𝐼𝑎 + [𝐹𝑐]+ 𝐾! − 𝐹𝑐𝛾𝑅𝐼𝐼𝐼𝑎 + [𝐹𝑐]+ 𝐾! ! − 4[𝐹𝑐𝛾𝑅𝐼𝐼𝐼𝑎][𝐹𝑐]2 𝐹𝑐𝛾𝑅𝐼𝐼𝐼𝑎  
Surface Plasmon Resonance 
GFP-FcγRIIIa was immobilized on the surface of a CM5 S Series chip using 
primary amine coupling in flow cells 2, 3, and 4 with a BiaCore T100 system (GE 
Healthcare). Flow cell 1 was left uncoupled as a reference cell. IgG1 Fc:FcγRIIIa 
dissociation constants were measured in triplicate by analysis of SPR response at 
 31 
equilibrium following subtraction of the signal from the uncoupled reference cell at 25 °C. 
At least five concentrations of each sample were injected onto the chip surface at a flow 
rate of 5 µl/min with a contact time of 420 s and a dissociation time of 420 s. Chip 
regeneration was achieved by applying 10 µL of 100 mM Glycine, pH 3.0 in 30 s. 
Dissociation constants (KD) were determined by fitting Eq 2 to equilibrium response 
values. 
 
RUeq = RUmax/(1+[Fc]/KD)                                                                                  Eq. 2 
 
where RUeq is the measured response at equilibrium, [Fc] is the IgG1 Fc concentration, 
RUmax is the response when the chip is saturated with Fc. 
 
Results 
Glycan-polypeptide interface mutations 
Fc glycan-polypeptide interface mutants are well-folded 
F241, F243, K246, and D265 have been identified as residues in the Fc 
polypeptide that interact with the carbohydrate residues of the Fc N-glycan (105). To 
probe the role of these amino acid residue interactions, these residues were mutated. F241 
forms π-CH interactions with the 3 Man residue while F243 forms π-CH interactions 
with the 5` GlcNAc residue of the 1-6 arm (10,14,105). K246 forms a hydrogen bond 
with the same 5` GlcNAc residue. F241S, F243S, and F241S/F243S mutants were made 
to disrupt the π-CH interactions; F241I, F243I, and F241I/F243I mutations were made to 
disrupt the π-CH interactions while preserving the hydrophobicity at these residues. The 
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K246F mutations was made to replace the hydrogen bonding capabilities of K246 with a 
π-CH interaction. All Fc mutants appear to be well folded based on their ability to still 
bind protein A during the purification process. 
K246F and D265S have WT-like glycan distribution 
 K246F has a glycan distribution that is very similar to WT Fc. The relative 
abundance for the G0F is 73.2 and 73.6% for WT and K246F respectively (Figure 10 and 
Table 1a). G2F comprises 2.98% of the WT glycoforms and 2.56% of the K246F 
glycoforms. The only major difference is that WT has 23.9% G1F while K246F has only 
15.94% G1F. The other glycoforms identified in the mass trace of K246F were the under-
processed glycoforms NM3N2F (5.68%) and G1N3M3N2F (2.24%). Still, the K246F 
glycoforms are remarkably similar to WT in terms of being primarily G0F and galactose-
terminated. Likewise, the  D265S mutants is also primarily of the G0F glycoform, but 
appears to lack G2F.  
F241, F243, and D265A mutants have highly processed glycans 
 The core structure of the Fc N-glycan is a GlcNAc terminated, fucosylated form 
that is called the G0F form. The G in this short term notation refers to the number of 
terminal galactose residues. As galactose residues are added the glycoform is referred to 
as G1F, monogalactosyl, or G2F, digalactosyl Fc. The addition of sialic acid is noted with 
the letter A. Mono- and di- sialyl Fc are represented as A1G2F and A2G2F respectively. 
Please refer to table 1 in the results for cartoon representations of these structures with 
their short-hand notation. 
The F241 and F243 series of mutants have a more diverse and extensively 
processed glycoform distribution that WT (Figure 10 and Table 1). The abundance of 
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G0F is significantly decreased in all F241 and F243, ranging from 35.31% for F241I all 
the way down to 8.63% for the F241I/F243I double mutant. The F241S, F243S, and 
F241S/F243S mutants also had decreased levels of the G0F form (20.2%, 27.4%, and 
10.42% respectively). This decrease in the abundance of G0F is accounted for in a great 
increase in galactose-terminated and sialic acid-terminated glycans for the F241 and F243 
mutants. The F241I mutant has a total of 49.86% galactose-terminated glycoforms. Only 
6.42% of the F241I mutant were sialic acid-terminated, with no diasialyl Fc detected. The 
F243S mutant was fairly similar to the F241I mutant in terms of being predominantly 
galactose-terminated (45.9% of total glycoforms) and has a 9.16% of the A1G2F 
glycoform, but lacks disialyl Fc. The F241S and F243I mutants are similar in terms of 
glycan distribution. Both mutants are dominated by galactose-terminated glycoforms with 
F241S having 44.0% galactose-terminate glycans and F243I having 50.5% galactose-
terminated glycans. They also have a significantly higher abundance of sialic acid-
terminated glycans versus Wt Fc, F241I, and F243S. F241S has 28.7% sialic acid-
terminated glycans with 9.04% diasialyl. F243I has 24.9% sialic acid-terminated glycans 
and 7.49% disialyl. The F241/F243 double mutants have a dramatically increased 
diversity in Fc glycoforms, with 30 different glycoforms being identified for the 
F241I/F243I mutant and 28 for the F241S/F243S double mutant. Both double mutants are 
predominantly sialic acid-terminated, exhibiting monosialyl, disialyl, and even trisialyl 
glycans. F241I/F243I is 52.3% and F241S/F243S is 55.0% sialic acid-terminated. Overall, 
the general trend is the more severe the mutation, the more highly processed the 
glycoforms are and the broader the glycan distribution. D265A has a small amount of 
sialylated Fc, but is primarily G0F, G1F and G2F. 
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Figure 10: Glycan analysis for Fc polypeptide-glycan interface mutants. Glycans were cleaved from the 
polypeptide using PNGaseF. The cleaved glycans were permethylated, and masses were analyzed via 
MALDI-TOFMS. See Table 1 for glycoforms and mass values of individual peaks. 
 
Fc glycan-polypeptide mutants have modified affinity for FcγRIIIa 
 Wt Fc and the mutants are expressed with a heterogeneous distribution of 
glycoforms. Enzymatic remodeling of Fc N-glycans has been used to make homogenous 
glycan distributions (15,24,27,116). To remove the variability of heterogeneous 
glycoforms and prepare samples for binding assays, all Fc samples were remodeled to the 
G2F glycoform. WT IgG1 Fc affinity for FcγRIIIa was measured by ITC (1.2 ± 0.1 µM), 
pull-down (0.5 µM), and SPR (0.55 ± 0.05 µM). This multi-method approach was used to 
confirm the fidelity of the Fc-FcγRIIIa interaction for the WT protein. SPR was used to 
measure the affinity of the Fc mutants. K246F has similar, if mildly greater, affinity for 
FcγRIIIa as WT (Kd = 0.34 ± 0.1 uM) (Figure 11). The F241/F243 series of mutants all 
have impaired binding to  
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Table 1: relative abundance of glycans from figure 10. 
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Table 1 (continued) Glycoform	   D265A	   D265S	  G0F	   32.9	   60.2	  G1F	   27.4	   32.9	  G2F	   24.4	   6.9	  A1G2F	   9.9	  
	  A2G2F	   5.4	  
	   
FcγRIIIa. The single mutants F241I, F241S, and F243S have a 3-4 fold reduction in 
affinity versus wild type (Figure 11). The affinity of F241I/F243I decreased 20-fold and 
the F241S/F243S double mutant had a 58-fold decrease. 
 To demonstrate the primary effect is due to disruption of glycan-polypeptide 
interactions, and not due to mutations, the affinity of HEK293S expressed, EndoF1 
treated WT Fc, F241I/F243I, and F241S/F243S FcγRIIIa were measured by SPR. These 
samples have only the initial GlcNAc residue in their glycan. WT Fc had an affinity of 
2.4 ± 0.2 µM, F241S/F243S had an affinity of 3.5 ± 0.9 µM, and F241I/F243I had an 
affinity of 6.3 ± 0.6 µM. The aglycosylated Fc mutant, T299A, was tested for binding by 
SPR and no binding was detected (Fig 11). The D265A and D265S mutants had no 
detectable binding by SPR or pull-down experiment. 
 
Mutations at the Cγ2-Cγ3 Interface 
Cγ2-Cγ3 Interface mutants are well-folded and express WT-like glycans 
 L251A, L251I, E430A, and E380A/E430A were all expressed in HEK293F cells 
and are well-folded based on their ability to bind to a protein A column through a well-
defined protein:protein interface that requires folded Fc. An attempt was made at making 
the E430A single mutations, however expression of this construct failed after many 
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efforts. The glycan composition profiles of all mutants were tested by MALDI-TOFMS 
and revealed WT-like glycoforms (Table 2). 
 
 
Figure 11: Sample binding curve of IgG1 Wt from SPR equilibrium binding experiments. 
The table contains the dissociation constants for each Fc mutant. 
 
 
 38 
Table 2: Glycan analysis and binding data for Fc interface mutants Glycoform	   Mass	  (monosiotopic)	   L251I	   L251A	   E430A	   E380A/E430A	  G0F	   1836	   85.4	   85.9	   84.9	   76.6	  G1F	   2040	   14.6	   14.1	   15.1	   23.4	  
 
Mutant	   Kd,	  uM	   Error	  
WT	   0.5	   0.01	  
L251A	   5.6	   0.6	  
L251I	   2.3	   0.4	  
E430A	   nb	  
	  E380A	  E430A	   nb	  
	   
E430A and E380A/E430A have impaired binding to FcγRIIIa 
 Binding of E430A and E380A/E430A were tested by protein A pull-down assay. 
No measurable binding was possible via this approach. SPR was not attempted with these 
mutants. However, the results of the pull-down assay allow us to place a limit on the 
possible binding of the E430A, E380A/E430A mutants. Due to the inherent error in the 
measurements for low-affinity binding (mid to high micromolar), the pull-down assay 
does not appear sensitive to Kds above 40 uM. 
L251A and L251I have reduced, but measurable binding, to FcγRIIIa 
 Because L251A and L251I glycan profiles were similar to WT, no glycan 
remodeling was performed. Additionally, these residues are not near the glycan-
polypeptide interface, and were not expected to influence glycan motions or processing. 
The affinities of L251A and L251I for GFP-FcγRIIIa were determined by SPR. L251A 
had a 10-fold decrease in affinity for FcγRIIIa while L251I had a 5-fold decrease in 
affinity.  
 
 
 39 
Discussion 
Fc Polypeptide-Glycan Interface 
 Disruption of the intramolecular polypeptide-glycan interactions in Fc has 
structural ramifications in terms of glycan composition, and FcγRIIIa binding site 
formation. Single amino acid mutations at these points of contact have considerable 
effects on glycan processing. Mutating F241 or F243 to alanine have significant impact 
on their glycan profiles, resulting in highly sialylated glycoforms (10,18). F to A is a 
rather severe mutation based on the Gonnet matrix (127). However, F to S is considered 
more severe, but we do not see as elaborate of glycoforms in our F241S and F243S single 
mutations. The F241S/F243S double mutant was determined to have trisialyl glycans, 
similar to the F241A and F243A mutants in Yu’s study (10). It could be that in the 
F241A/S single mutant the F243 amino acid is able to maintain contacts with the glycan 
that somewhat compensate for the perturbation to the intramolecular interaction and vice 
versa. This would suggest the F241 and F243 effects are somewhat additive. The affect of 
mutations appears to be position specific. F241S has more highly processed glycans than 
F241I, but F243I has more highly processed glycans than F243S. Suggesting that 
maintenance of the hydrophobicity at position 241 is more important than at residue 243. 
This could also be due to the mutations influencing the glycosyltranferase-Fc 
intermolecular interactions rather than glycan-polypeptide intramolecular interactions of 
Fc. 
 Mutations of residues F241 and F243 not only affected N-glycan processing 
during protein expression, but also reduced affinity for FcγRIIIa. Single mutations have a 
relatively moderate effect, reducing the affinity 3-4 fold. Double mutants have a more 
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severe affect. F241I/F243I has a 20-fold decreased affinity for FcγRIIIa and 
F241S/F243S has a 53-fold decrease in affinity. NMR studies published by our lab 
indicate that this reduction in affinity is strongly correlated with increased mobility of the 
glycan chain termini (116). The F241/F243 double mutants disrupt distal glycan-
polypeptide interactions at residue 243 and also medial glycan-polypeptide interactions at 
residue 241. It is our theory that promoting mobility of the glycans perturbs the C`E loop 
structure, which has broader ramifications on the formation of an appropriate FcγRIIIa 
binding site. When the glycan is more mobile, the C`E loop has more conformational 
freedom and perhaps adopts fewer binding-favorable conformations. This conformational 
freedom could extend to the entire Cg2 domain. Currently, we lack the observations of 
Cg2 domain motions to say one-way or another.  
 This idea of local C`E conformation is supported by our studies of the D265A and 
D265S mutants. These amino acid residues interact with the first GlcNAc residue 
(attached directly to N297) via a hydrogen bond. Based on NMR data from our lab, 
mutation of D265 has minor impact on distal glycan motions (Subedi and Barb, 
unpublished observation). However, the Fc D265A dimer does not bind to FcγRIIIa in 
vitro (30,46). This suggests that a conformational change at or near the C`E loop disrupts 
the formation of the FcγRIIIa binding site. Immune complexes of IgG1 containing the 
D265A are still able to weakly interact with B-cells (42). Indicating that some binding-
favorable conformations are still assumed by Fc D265A. Combined with our evidence 
that HEK293S, EndoF1 treated Fc mutants can still bind FcγRIIIa, our data suggest that 
proximal glycan-polypeptide interactions play a vital role in Fc functionality. The 
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importance of proximal glycan-polypeptide interaction has also been demonstrated in 
protein folding (128,129).  
 The Fc glycan-polypeptide interaction plays an important role in Fc function. 
These intramolecular interactions can be divided to into proximal and distal interaction. 
Distal interactions mediated by residues F241, F243, and K246, appear to restrict the 
mobile 1-6 arm of the glycan, reducing the motions of the entire N-glycan. This lack of 
mobility stabilizes Fc C`E and/or Cg2 conformations, resulting in FcγRIIIa binding-
favorable conformations. Meanwhile, proximal glycan-polypeptide interactions have 
little influence upon overall glycan mobility, but may impact C`E loop conformations 
more directly. It is evident that both proximal and distal interactions are important for Fc-
FcγRIIIa binding. 
 
Cγ2-Cγ3 Interface 
 The Cγ2-Cγ3 interface is rather limited, comprising two salt-bridges formed 
between E380-K248 and E430-K338 and a “ball-in-socket” joint. We removed the salt 
bridges via the E430A and E380A/E430A mutants. We were unable to measure binding 
between these mutants and FcγRIIIa using a pull-down assay. The E430A has previously 
been reported to only influence FcγRIIIa binding, but mutating the salt-bridge partner of 
E430, K338, did disrupt FcγRIIIa binding (30). However, our data indicate that Fc 
FcγRIIIa binding is also affected through the E430A mutation. These differences may be 
attributed to the fact that our experiment was performed using isolated Fc, while the work 
of Shields and colleagues was done with IgG. In isolated Fc, mutating E430 and/or E380 
is thought to disrupt the horseshoe shape formed by Fc and result in floppy Cγ2 domains. 
 42 
MD simulations of an E380A/E430A Fc mutant depict increased motions of the Cγ2 
domains relative to wt Fc (4). However, bench-top evidence of these overall Cγ2 domain 
motions is lacking. 
 Elbow-like motions of the Cγ2 domains relative to the Cγ3 domains are restricted 
by the Cγ2-Cγ3 interface. L251 has been identified to participate in a ball-in-socket-like 
joint at the interface that helps guide these motions (17). A similar structural motif is 
found between the variable and constant domains of Fab, where a ball-in-socket joint 
results in elbow-like motions (130). In Fc, mutation of L251 to I or A reduces the affinity 
for FcγRIIIa by a moderate amount. L251 functions as the “ball” in the molecular “ball-
in-socket” joint. L251I may change the shape of the “ball” enough to have a minor 
influence on Cγ2 domain motions, while L251A eliminates the joint entirely allowing for 
more freedom of motion in the Cγ2 domain. No molecular simulations have been done 
using these mutants, so the disruption of overall Cγ2 domain motions is mostly 
speculation. 
 IgG1 is a dynamic molecular system. The interaction between Fc and FcγRs 
appears to be influence by a complex set of variables including glycan composition, 
glycan motions, domain conformations, and domain motions. Key interaction sites within 
the Fc system affect these variables. For example, the conformation of the C`E loop on 
the Cγ2 domain may be influenced by the intramolecular glycan-polypeptide interactions. 
Within these intramolecular interactions, there are affects due to proximal and distal 
glycan interactions. Cγ2 orientation and motions may be guided by the Cγ2-Cγ3 interface, 
where salt bridges stabilize the interaction and a “ball-in-socket” joint guides the 
interactions. 
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CHAPTER 3 
DESIGN AND IMPLIMENTATION OF mIgG2a IMMUNE COMPLEXES  
Introduction 
In the previous chapter, we looked at the monovalent affinity of hIgG1 Fc for FcγRIIIa in 
vitro. In vivo, an immune response requires multivalent interactions between many IgGs 
and many FcγRs on the surface of a cell. This is actually good. If monomeric binding of 
Fc activated the immune system, everyone would suffer from chronic systemic 
inflammation. Thus, Fc binding is avidity driven. Here we will discuss the preparation of 
multivalent ligands to probe the immune system in vivo. These antibody aggregates are 
called immune complexes. 
mIgG2a is the mouse homologue to hIgG1. For this project, we used mIgG2a to 
make artificial ICs for our collaborators to use with mouse cells. For us, this was a proof-
of-concept, that we could make artificial ICs so we could clone our hIgG1 Fcs into this 
construct to do our own cellular studies. Artificial cross-linking of Fc has been done 
previously to test the effect of immune complex size and glycosylation on immune cell 
activation (42,61). This has been done by using anti-Fc Fab domains to cross-link 
engineered Fc proteins. We decided to use a biotinylation strategy to cross-link mIgG2a 
Fc to create immune complexes because it does not require us to engineer Fabs. 
 
Methods 
Construct design 
 The mIgG2a and mIgG2aHA constructs have a modular design with an N-
terminal and C-terminal segments (Fig 12). The N-terminal segment contains a TCM 
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signal sequence, followed by an 8x His tag, and Avi recognitions sequence and GFP. 
This is connected to the C-terminal segment by a TEV cleavage site. The C-terminal 
segment comprises a second Avi site followed by mIgG2a Fc. The mIgG2a-HA construct 
contains all of the previously mentioned features, with the addition of a 4x hemagglutinin 
tag at the C-terminus. mIgG2a and mIgG2a-HA were each cloned into the NotI/BamHI 
site of the pGen2 vector. Construct integrity was verified by sequencing at the ISU DNA 
Facility. 
 
Protein expression and purification 
 pGen2:mIgG2a and pGen2:mIgG2aHA were expressed in by transient 
transfection in HEK293F cells as explained in chapter 2 methods. Proteins were 
harvested as previously stated and purified on a Ni-NTA column.  
 
 
Figure 12: Modular design of the mIgG2a(HA) constructs. 
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Glycan Analysis 
 See chapter 2 
Biotinylation and Cross-linking 
 The Avi tag in the mIgG2a construct serves as a biotinylation site for the biotin 
ligase, BirA. mIgG2a was biotinylated and cross-linked using streptavidin. Purified GFP-
mIgG2a was biotinylated using the BirA500 kit (Avidity). Excess biotin was removed 
from the reaction by buffer exchanging the sample in a 15 mL Amicon tube to an 
effective dilution of 2000x in 10 mM potassium phosphate (pH 7.0), 150 mM sodium 
chloride. The extent of biotinylation was monitored using a small aliquot from the sample 
and applying it to a 100 µL Avi column to determine the ratio of biotinylated product that 
bound to the column (unreacted Fc does not bind). This was routinely found to be >95%. 
The final biotinylated product was cross-linked using a molar ration of 3.5 GFP-mIgG2a 
Fc to 1 streptavidin tetramer. 
Complex size analysis 
 Cross-linked complex size were determined by dynamic light scattering (DLS), 
and size exclusion chromatography multi-angle light scattering (SEC-MALS). 100 µL of 
the cross-linked sampled and 100 µL of not cross-linked GFP-mIgG2a were each placed 
into disposable DLS cuvettes. The mass average was determined by measuring the light 
scattering in the cuvette 5-10 times for 60 seconds each. SEC-MALS was done by 
running the complexes over a WTC-200S size exclusion column.  
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Results 
Expression of mIgG2a Constructs 
 Both mIgG2a and mIgG2aHA constructs were expressed in HEK293F cells. The 
glycan profiles for both constructs were primarily G0F, similar to Wt hIgG1 Fc (Fig 13). 
mIgG2aHA, unfortunately, appeared to degrade during expression and formed large 
aggregates when boiled (Figure 14). Additionally, centrifugation of the mIgG2aHA 
protein resulted in the formation of a white pellet a few days after expression. Due to this 
instability the mIgG2aHA construct was not used for future experiments. The mIgG2a 
construct, on the other hand, appears to be stable for several months at 4C in sterile 
phosphate buffer. 
 
mIgG2a can be cross-linked to form soluble immune complexes 
 Each mIgG2a dimer had four biotinylation sites, providing us with four potential 
handles to cross-link mIgG2a Fc using streptavidin. DLS was initially used to determine 
the size of mIgG2a immune complexes. However, the results were inconsistent. 
Therefore, we used SEC-MALS to analyze IC mass. 
 To get a better measurement of the actual IC size, SEC-MALS was used. The 
validity of the SEC-MALS approach was first tested using a thyroglobulin standard. The 
mass of thyroglobulin was measured to be 638 kDa by light scattering, which is 3.33% 
error from the actual mass of 660 kDa. Uncomplexed mIgG2a Fc was determined to have 
a mass of 126 kDa by light scattering. mIgG2a complexes had two nearby peaks in the 
light scattering instrument. The first peak was at 1139 kDa, which is between 7-9 Fc units 
per complex. The second peak was at 723 kDa, which indicated 4-5 Fc units per immune 
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complex. Interestingly, if you took the average mass of the two peaks, the mass was 
consistent with 7.5 Fc units per complex. 
 
 
Figure 13: Glycan analysis of mIgG2a constructs indicates a primarily G0F glycoform. Glycans were 
isolated from mIgG2a(HA) using PNGaseF, then permethylated for MALDI-TOFMS analysis. 
Discussion 
 The mIgG2a constructs were created for our collaborators, Profs Doug Jones and 
Brett Sponseller (ISU Veterinary Medicine), to create artificial, soluble immune 
complexes. For our purposes, they were a proof-of-concept that we could eventually use 
to provide a potential platform for looking at Fc functionality using cellular systems. A 
modular approach was taken provide multiple options for creating immune complexes. 
The HA tag in mIgG2aHA was originally included in hopes of using Anti-HA (Fab)2 
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domains to cross-link the complex. However, that feature turned out to present significant 
limitations with respect to complex stability. 
 
 
Figure 14: mIgG2aHA is less stable than mIgG2a and undergoes spontaneous 
degradation. A) Supernatants from HEK293F transfection were stored on each indicated 
day at -80C. When all samples were collected, 10µL of the supernatant was combined 
with 2 µL of Lamaelli buffer and the samples were boiled for 5 minutes before 
performing SDS-PAGE. B) Samples were purified using a Ni-NTA column, then 
prepared for SDS-PAGE as in part A. The +BME samples were supplemented with 5% 
BME before boiling. 
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Figure 15: SEC-MALS analysis of mIgG2a immune complexes. Peak 1 corresponds to a mass of 1139 kDa, 
peak 2 corresponds to a mass of 723 kDa. 
 
 The presence of GFP provided a useful tool for using cell imaging to track the 
localization of immune complexes when cells were treated. The TEV recognition 
sequence between the GFP and mIgG2a Fc segments was included to remove the GFP if 
necessary for other experiments. Both GFP and mIgG2a Fc segments contained Avi sites 
so that we could still cross-link mIgG2a Fc using streptavidin after removal of the GFP. 
Additionally, removal of the GFP and its Avi sequon could potentially allow us to make 
smaller immune complexes by reducing the number of available biotin sites from four to 
two. However, the current state of the construct appears to be useful for our collaborators. 
The GFP is used for confocal microscopy and the size of the immune complexes we 
provide them is suitable for their needs. 
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Table 3: Theoretical IC complex sizes based on possible number of mIgG2a Fc and streptavidin. Red 
highlights are complex compositions that could be encompassed in peak 2, yellow highlights are consisten 
with masses that could be found in peak 1. All masses between peaks 1 and 2 are possible. The highlighted 
regions simply correspond to peak locations ± 10% kDa. 
#	  mIgG2a	  Fc	   #	  Streptavidin	   IC	  Mass,	  kDa	  
2	   1	   287.6	  
2	   2	   339.6	  
3	   2	   457.4	  
3	   3	   509.4	  
4	   2	   575.2	  
4	   3	   627.2	  
4	   4	   679.2	  
4	   5	   731.2	  
4	   6	   783.2	  
5	   2	   693	  
5	   3	   745	  
5	   4	   797	  
5	   5	   849	  
5	   6	   901	  
6	   2	   810.8	  
6	   3	   862.8	  
6	   4	   914.8	  
6	   5	   966.8	  
6	   6	   1018.8	  
6	   7	   1070.8	  
6	   8	   1122.8	  
7	   2	   928.6	  
7	   3	   980.6	  
7	   4	   1032.6	  
7	   5	   1084.6	  
7	   6	   1136.6	  
7	   7	   1188.6	  
8	   3	   1098.4	  
8	   4	   1150.4	  
8	   5	   1202.4	  
9	   3	   1216.2	  
9	   4	   1268.2	  
9	   5	   1320.2	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